PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma
Journal of Clinical Oncology · 10.07.2025 · 43 (20) · 2255-2264
DOI: 10.1200/jco-24-02210 ↗Kurz gefasst
Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.07.2025. Verfasst von Michel Ducreux und 19 weiteren Autor:innen. Beteiligte Einrichtung: Gustave Roussy Cancer Center, Tumor Cells Dynamics, INSERM U1279, Université Paris-Saclay, Villejuif, France. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Deoxycytidine. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 25 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
PURPOSE More than 30% of patients with pancreatic cancer are unresectable because of the local extension with a median overall survival (OS) of 60 years). Patients received FOLFIRINOX or gemcitabine for 6 months. The primary end point was progression-free survival (PFS). Main secondary end points were OS, time to treatment failure, quality of life, and safety. One hundred seventy patients (142 events) were needed to detect an increase of 3 months in PFS with 80% power (log-rank test, 5% two-sided α). RESULTS One hundred seventy one patients age 35-84 years were included and followed for a maximum of 5 years. With a median follow-up of 59.6 months (95% CI, 42.3 to not reached), 168 events were observed and the median PFS was 9.7 months (95% CI, 7.0 to 11.7) with FOLFIRINOX versus 7.7 months (95% CI, 6.2 to 9.2) with gemcitabine, hazard ratio (HR), 0.7 (95% CI, 0.5 to 1.0), P = .04. The median OS was 15.7 months (95% CI, 11.9 to 20.4) in the FOLFIRINOX group versus 15.4 months (95% CI, 11.7 to 18.6) in the gemcitabine group, HR, 1.02 (95% CI, 0.73 to 1.43), P = .95. CONCLUSION Results confirm that FOLFIRINOX improves PFS significantly compared with gemcitabine and is well tolerated in LAPC. No significant difference in OS was observed between both groups.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Gustave Roussy Cancer Center, Tumor Cells Dynamics, INSERM U1279, Université Paris-Saclay, Villejuif, France.
- Hepato-Gastroenterology and Digestive Oncology Department, Centre Hospitalier de Saint Malo, Saint Malo, France.
- Oncology, Hôpital Européen, Marseille, France.
- Gastroenterology, CHU Hôpitaux de Rouen-Charles Nicolle, Rouen, France.
- Digestive Oncology, Centre Hospitalier Rangueil, Toulouse, France.
- Medical Oncology, Centre Antoine Lacassagne, Nice, France.
ORCID-Profile: Michel Ducreux, Rosine Guimbaud, Jean-Baptiste Bachet, Thierry Lecomte, Olivier Capitain, Matthieu Texier, Olivier Bouche
Zitieren
APA
Ducreux, M., Desgrippes, R., Rinaldi, Y., Di Fiore, F., Guimbaud, R., Evesque, L., Bachet, J. B., Vanelslander, P., Lecomte, T., Capitain, O., Parzy, A., Bolliet, M., Etienne, P. L., Forestier, J., El Hajbi, F., Bignon, A. L., Lebrun-Ly, V., De Sousa Carvalho, N., Texier, M., & Bouche, O. (2025). PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma. Journal of Clinical Oncology, 43(20), 2255-2264. https://doi.org/10.1200/jco-24-02210
Vancouver
Ducreux M, Desgrippes R, Rinaldi Y, Di Fiore F, Guimbaud R, Evesque L, et al. PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma. Journal of Clinical Oncology. 2025;43(20):2255-2264. doi:10.1200/jco-24-02210
BibTeX
@article{Ducreux2025,
author = {Ducreux, Michel and Desgrippes, Romain and Rinaldi, Yves and Di Fiore, Frédéric and Guimbaud, Rosine and Evesque, Ludovic and Bachet, Jean-Baptiste and Vanelslander, Pierre and Lecomte, Thierry and Capitain, Olivier and Parzy, Aurélie and Bolliet, Marion and Etienne, Pierre-Luc and Forestier, Julien and El Hajbi, Farid and Bignon, Anne-Laure and Lebrun-Ly, Valérie and De Sousa Carvalho, Nicolas and Texier, Matthieu and Bouche, Olivier},
title = {PRODIGE 29-UCGI 26 (NEOPAN): A Phase III Randomized Trial Comparing Chemotherapy With FOLFIRINOX or Gemcitabine in Locally Advanced Pancreatic Carcinoma},
journal = {Journal of Clinical Oncology},
year = {2025},
volume = {43},
number = {20},
pages = {2255--2264},
doi = {10.1200/jco-24-02210}
}
EUVIMED